48,872
edits
Difference between revisions of "Fibroblast growth factor receptors"
Jump to navigation
Jump to search
Fibroblast growth factor receptors (view source)
Revision as of 16:22, 8 March 2024
, 16:22, 8 March 2024no edit summary
| Line 3: | Line 3: | ||
An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal |vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A |title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review |journal=J Cancer Res Clin Oncol |volume=149 |issue=8 |pages=4915–4923 |date=July 2023 |pmid=36307559 |doi=10.1007/s00432-022-04428-w |url=}}</ref><ref name=pmid33731335>{{cite journal |vauthors=Al-Obaidy KI, Cheng L |title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder |journal=J Clin Pathol |volume=74 |issue=8 |pages=491–495 |date=August 2021 |pmid=33731335 |doi=10.1136/jclinpath-2020-207115 |url=}}</ref> | An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal |vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A |title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review |journal=J Cancer Res Clin Oncol |volume=149 |issue=8 |pages=4915–4923 |date=July 2023 |pmid=36307559 |doi=10.1007/s00432-022-04428-w |url=}}</ref><ref name=pmid33731335>{{cite journal |vauthors=Al-Obaidy KI, Cheng L |title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder |journal=J Clin Pathol |volume=74 |issue=8 |pages=491–495 |date=August 2021 |pmid=33731335 |doi=10.1136/jclinpath-2020-207115 |url=}}</ref> | ||
Anti-FGFR therapy is used in: | ==Anti-FGFR therapy== | ||
It is used in: | |||
*[[Urothelial carcinoma]].<ref name=pmid33731335/> | *[[Urothelial carcinoma]].<ref name=pmid33731335/> | ||
*Hepatobiliary cancers.{{fact}} | *Hepatobiliary cancers.{{fact}} | ||